Coherus BioSciences Partners with STORM Therapeutics on LOQTORZI/STC-15 Combination Study.

Coherus BioSciences has partnered with STORM Therapeutics to evaluate the METTL3 inhibitor STC-15 in combination with Coherus' PD-1 inhibitor LOQTORZI for the treatment of non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, and endometrial cancer. The Phase 1b/2 study aims to assess the safety and efficacy of the combination therapy.

Coherus BioSciences (NASDAQ: CHRS) has entered a clinical collaboration with STORM Therapeutics to evaluate the combination of STC-15, a METTL3 inhibitor, and LOQTORZI, Coherus' next-generation PD-1 inhibitor, in a Phase 1b/2 study targeting multiple cancer types. The study aims to assess the safety and efficacy of the combination therapy for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, and endometrial cancer.

The Phase 1b study will enroll up to 188 patients in the United States, with the first patient already dosed. Coherus will provide LOQTORZI while STORM will sponsor the trial. Both companies retain commercial rights to their respective compounds. The study will initially focus on safety and efficacy in Phase 1b before expanding into multiple cancer types in Phase 2.

The collaboration is notable for its strategic alignment, with Coherus seeking to expand the indications for LOQTORZI beyond nasopharyngeal carcinoma (NPC) through cost-efficient drug supply agreements. The combination of STC-15 and LOQTORZI represents a novel approach to cancer treatment, potentially overcoming resistance mechanisms seen with PD-1 monotherapy.

This partnership underscores Coherus' commitment to advancing its pipeline and driving sales multiples and synergies through proprietary combinations. The company's immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses.

For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit [www.loqtorzi.com](http://www.loqtorzi.com).

References:
[1] https://www.stocktitan.net/news/CHRS/coherus-announces-clinical-collaboration-with-storm-therapeutics-to-xxpiwxdnmomm.html